Clinical Trial Update: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial [Phase 3]

View source ↗

Summary

Phase 3 PK subtrial in adolescents with hereditary angioedema participating in the KVD900-302 trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• KVD900 (Sebetralstat)

Snippet

Sponsor: KalVista Pharmaceuticals, Ltd. | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED